35 articles for thisTarget
The following articles (labelled with PubMed ID or TBD) are for your review
PMID
Data
Article Title
Organization
Progress in the development of fatty acid synthase inhibitors as anticancer targets.
University of South Alabama
Fatty Acid Synthase (FASN) Inhibitors as Potential Treatment for Cancer, Obesity, and Liver Related Disorders.
Therachem Research Medilab (India)
Repositioning proton pump inhibitors as anticancer drugs by targeting the thioesterase domain of human fatty acid synthase.
Indiana University School of Medicine
Design, synthesis, and biological and crystallographic evaluation of novel inhibitors of Plasmodium falciparum enoyl-ACP-reductase (PfFabI).
University of Bologna
Imidazopyridine-Based Fatty Acid Synthase Inhibitors That Show Anti-HCV Activity and in Vivo Target Modulation.
3-V Biosciences
Fatty acid synthase inhibitory activity of acylphloroglucinols isolated from Dryopteris crassirhizoma.
Korea Research Institute of Bioscience and Biotechnology
Inhibition of Plasmodium falciparum fatty acid biosynthesis: evaluation of FabG, FabZ, and FabI as drug targets for flavonoids.
University of Zurich
Structure-activity relationships at the 5-position of thiolactomycin: an intact (5R)-isoprene unit is required for activity against the condensing enzymes from Mycobacterium tuberculosis and Escherichia coli.
National Institute of Allergy and Infectious Diseases
Synthesis and evaluation of analogues of S-adenosyl-L-methionine, as inhibitors of the E. coli cyclopropane fatty acid synthase.
Universit£
Discovery of BI 99179, a potent and selective inhibitor of type I fatty acid synthase with central exposure.
Boehringer Ingelheim Pharma
2-Hexadecynoic acid inhibits plasmodial FAS-II enzymes and arrests erythrocytic and liver stage Plasmodium infections.
University of London
Fatty acid synthase inhibitors of phenolic constituents isolated from Garcinia mangostana.
Chinese Academy of Sciences
Novel fatty acid synthase (FAS) inhibitors: design, synthesis, biological evaluation, and molecular docking studies.
Institute of Pharmacology and Toxicology
1-Oxo-3-substitute-isothiochroman-4-carboxylic acid compounds: synthesis and biological activities of FAS inhibition.
Institute of Pharmacology & Toxicology
3-Aryl-4-hydroxyquinolin-2(1H)-one derivatives as type I fatty acid synthase inhibitors.
Merck Research Laboratories
Therapeutic Activity of the Lansoprazole Metabolite 5-Hydroxy Lansoprazole Sulfide in Triple-Negative Breast Cancer by Inhibiting the Enoyl Reductase of Fatty Acid Synthase.
Indiana University School of Medicine
Discovery and optimization of novel piperazines as potent inhibitors of fatty acid synthase (FASN).
Forma Therapeutics
Synthesis, biological activities, and docking studies of d-pantolactone derivatives as novel FAS inhibitors.
Third Institute of Oceanography
Application of a flexible synthesis of (5R)-thiolactomycin to develop new inhibitors of type I fatty acid synthase.
Johns Hopkins University
Design and synthesis of a series of bioavailable fatty acid synthase (FASN) KR domain inhibitors for cancer therapy.
Janssen Research and Development
A strategy for dual inhibition of the proteasome and fatty acid synthase with belactosin C-orlistat hybrids.
Baylor University
(-)-UB006: A new fatty acid synthase inhibitor and cytotoxic agent without anorexic side effects.
Yachaytech University